Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of Numax versus palivizumab for RSV prophylaxis in high-risk children
2004-000039-27Phase 3Completed
- Sponsor
- MedImmune
- Start
- Jul 2004
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of isoxsuprine and palivizumab in respiratory syncytial virus disease (RSV) (2 arms), sponsored by MedImmune. Primary endpoint: Incidence of RSV hospitalization. Started Jul 2004; status: completed.
02
Drugs
isoxsuprinepalivizumab
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on 2004-000039-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000039-27.